Corporate Overview

Arbios Systems, Inc. is developing proprietary medical devices and cell-based therapies to enhance the survival of millions of patients each year who experience, or are at risk for, life-threatening episodes of liver failure. 

The Arbios product candidate portfolio includes the SEPET™ Liver Assist Device, a novel blood purification therapy that provides enhanced “liver dialysis,” and the HepatAssist™ Cell-Based Liver Support System, a bioartificial liver that combines blood detoxification with liver cell therapy to provide replacement of whole liver function in patients with the most severe forms of liver failure.  Both products may provide the critical benefit of reducing the time that patients spend in a state of liver failure, thereby decreasing intensive care costs at hospitals and improving overall outcomes by minimizing or preventing damage to the liver.  SEPET™ may have further utility in treating sepsis, multi-organ failure, and related inflammatory disorders.

Arbios currently trades on the OTC Bulletin Board under the symbol:  ABOS.

Arbios Investment Highlights

• Pure play in large, untapped liver failure market
  • “Liver Dialysis”
• Pioneering products meet a growing, unmet medical need
  • SEPET™ Liver Assist Device (feasibility / Phase 1-2)
  • HepatAssist™ Cell-Based Liver Support System  (pivotal / Phase 3)
• Clear, rapid regulatory paths with well-defined customer bases
• Experienced management team, Board of Directors and SAB
• Emerging proof-of-concept data for SEPET™ to complement established safety and efficacy data for HepatAssist™